SCHEMBL1996184

SCHEMBL1996184

N#Cc1ccc2ncc(-c3nccc(N[C@H]4CC[C@H](O)CC4)n3)n2c1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 5/20 0.58
IRAK1 P51617 2/20 0.58
FLT3 P36888 2/20 0.54
PIM1 P11309 2/20 0.51
MAPK8 P45983 1/20 0.46
MAPK9 P45984 1/20 0.46
EIF2AK4 Q9P2K8 3/20 0.45
JAK2 O60674 7/20 0.44
JAK3 P52333 7/20 0.44
JAK1 P23458 5/20 0.44
LCK P06239 1/20 0.41
RET P07949 1/20 0.41
PDGFRB P09619 1/20 0.41
CDK7 P50613 1/20 0.41
BLK P51451 1/20 0.41
CCNH P51946 1/20 0.41
KCNH2 Q12809 1/20 0.41
MERTK Q12866 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1996185 1.00 IRAK4 (0.58) IRAK4IRAK1FLT3PIM1MAPK8
SCHEMBL1997583 0.90 IRAK4 (0.60) IRAK4IRAK1FLT3EIF2AK4JAK2
SCHEMBL1996579 0.88 IRAK4 (0.58) IRAK4IRAK1FLT3EIF2AK4JAK2
SCHEMBL12611013 0.85 MAPK8 (0.48) IRAK4IRAK1FLT3PIM1MAPK8
SCHEMBL1997624 0.85 JAK2 (0.52) IRAK4IRAK1FLT3PIM1MAPK8
SCHEMBL1997620 0.85 JAK2 (0.52) IRAK4IRAK1FLT3PIM1MAPK8
SCHEMBL1990855 0.83 IRAK4 (0.75) IRAK4IRAK1FLT3EIF2AK4JAK2
SCHEMBL1996010 0.83 IRAK4 (0.75) IRAK4IRAK1FLT3EIF2AK4JAK2
SCHEMBL1993336 0.83 IRAK4 (0.75) IRAK4IRAK1FLT3EIF2AK4JAK2
SCHEMBL2036609 0.83 IRAK4 (0.54) IRAK4IRAK1FLT3EIF2AK4JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US claimed
EP-2338888-A1 Imidazopyridine derivatives as JAK inhibitors Almirall, S.A. (ES) 2011-06-29 EP claimed
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US disclosed
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US disclosed
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US disclosed
WO-2011076419-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2011-06-30 WO disclosed
EP-2338888-A1 Imidazopyridine derivatives as JAK inhibitors Almirall, S.A. (ES) 2011-06-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS JAK1, JAK2, JAK3 IRAK4 12/4885IRAK1 15/4885FLT3 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.